Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
1.
J Biomech Eng ; 141(9)2019 Sep 01.
Article in English | MEDLINE | ID: mdl-31242283

ABSTRACT

A mechanical approach is needed for understanding anorectal function and defecation. Fecal continence is achieved by several interacting mechanisms including anatomical factors, anorectal sensation, rectal compliance, stool consistency, anal muscle strength, motility, and psychological factors. The balance is easily disturbed, resulting in symptoms such as fecal incontinence and constipation. Novel technologies have been developed in recent years for studying anorectal function. Especially, the Fecobionics device, a simulated feces, has gained attention recently. This facilitates new analysis of anorectal mechanical function. In this study, a theoretical model is developed to analyze anorectal mechanophysiological data generated by the Fecobionics device. Theoretical approaches can enhance future interdisciplinary research for unraveling defecatory function, sensory-motor disorders, and symptoms. This is a step in the direction of personalized treatment for gastrointestinal disorders based on optimized subtyping of anorectal disorders.

2.
Pediatr Blood Cancer ; 65(1)2018 Jan.
Article in English | MEDLINE | ID: mdl-28905508

ABSTRACT

BACKGROUND: The purpose of this study was to determine the feasibility and tolerability of tandem courses of high-dose thiotepa with autologous hematopoietic cell rescue (AHCR) in patients with recurrent, refractory solid tumors who were ineligible for a single course of high-dose therapy due to greater than minimal residual disease. Patients with decreased hearing or poor renal function were eligible. PROCEDURE: Thiotepa was administered intravenously at a dose of 200 mg/m2 /day (6.67 mg/kg/day) daily for 3 days followed by AHCR. A second course of thiotepa was given 4 weeks later provided blood counts recovered sufficiently without evidence of tumor progression. RESULTS: Fifty-eight patients received 96 courses. Thirty-eight (65%) patients received two courses of therapy. Twenty-seven courses (28%) were administered completely in the outpatient setting. A toxic mortality rate of 3.4% was observed. Five of 26 patients with medulloblastoma were alive at a median of 35 months, whereas 21 patients died at a median of 11.7 months. Four of five patients with central nervous system germ cell tumors (CNS GCT) were alive 68-103 months following AHCR. CONCLUSIONS: Two cycles of high-dose thiotepa with AHCR were well tolerated even in these heavily pretreated patients. This therapy may provide prolonged survival in patients with recurrent malignant brain tumors, particularly medulloblastoma and CNS GCT.


Subject(s)
Brain Neoplasms , Hematopoietic Stem Cell Transplantation , Medulloblastoma , Thiotepa/administration & dosage , Adolescent , Adult , Autografts , Brain Neoplasms/mortality , Brain Neoplasms/therapy , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Infant , Male , Medulloblastoma/mortality , Medulloblastoma/therapy , Survival Rate , Thiotepa/adverse effects
3.
Dalton Trans ; 42(30): 10919-28, 2013 Aug 14.
Article in English | MEDLINE | ID: mdl-23787951

ABSTRACT

Symmetrical and unsymmetrical dithiocarbamato pyridine solvated and non-solvated complexes of indium(III) with the general formula [In(S2CNRR')3]·n(py) [where py = pyridine; R,R' = Cy, n = 2 (1); R,R' = (i)Pr, n = 1.5 (2); NRR' = Pip, n = 0.5 (3) and R = Bz, R' = Me, n = 0 (4)] have been synthesized. The compositions, structures and properties of these complexes have been studied by means of microanalysis, IR and (1)H-NMR spectroscopy, X-ray single crystal and thermogravimetric (TG/DTG) analyses. The applicability of these complexes as single source precursors (SSPs) for the deposition of ß-In2S3 thin films on fluorine-doped SnO2 (FTO) coated conducting glass substrates by aerosol-assisted chemical vapour deposition (AACVD) at temperatures of 300, 350 and 400 °C is studied. All films have been characterized by powder X-ray diffraction (PXRD) and energy dispersive X-ray analysis (EDX) for the detection of phase and stoichiometry of the deposit. Scanning electron microscopy (SEM) studies reveal that precursors (1)-(4), irrespective of different metal ligand design, generate comparable morphologies of ß-In2S3 thin films at different temperatures. Direct band gap energies of 2.2 eV have been estimated from the UV-vis spectroscopy for the ß-In2S3 films fabricated from precursors (1) and (4). The photoelectrochemical (PEC) properties of ß-In2S3 were confirmed by recording the current-voltage plots under light and dark conditions. The plots showed anodic photocurrent densities of 1.25 and 0.65 mA cm(-2) at 0.23 V vs. Ag/AgCl for the ß-In2S3 films made at 400 and 350 °C from the precursors (1) and (4), respectively. The photoelectrochemical performance indicates that the newly synthesised precursors are highly useful in fabricating ß-In2S3 electrodes for solar energy harvesting and optoelectronic application.

4.
Conn Med ; 75(9): 517-21, 2011 Oct.
Article in English | MEDLINE | ID: mdl-22308637

ABSTRACT

BACKGROUND: High levels of the carcinogenic organochlorine pesticides chlordane and dieldrin have been reported in the well water of homes in North Stamford. It is unclear if the contamination is associated with an increase in the cancer rate in North Stamford. METHODS: We reviewed the demographics of the towns surrounding North Stamford and chose New Canaan, Wilton, Weston, and Darien as towns with sufficiently similar demographics that would permit comparison of cancer incidence with North Stamford. Data were obtained from the Connecticut Tumor Registry regarding the number of different cancers diagnosed per year from 1998 to 2007 in North Stamford and the four nearby towns. We compared the annual cancer incidence of these communities in total and by cancer types. RESULTS: There was no statistically significant difference in the average annual cancer incidence from 1998 to 2007 between North Stamford and the four other communities. There was also no statistically significant difference seen in the incidence of the various cancer types. CONCLUSION: Chlordane and dieldrin contamination of the well water of homes in North Stamford may not be associated with a higher incidence of cancer.


Subject(s)
Chlordan/toxicity , Dieldrin/toxicity , Insecticides/toxicity , Neoplasms/epidemiology , Water Pollutants, Chemical/toxicity , Water Supply , Aged , Chi-Square Distribution , Connecticut/epidemiology , Environmental Exposure , Female , Humans , Incidence , Male , Neoplasms/chemically induced , Registries
5.
Theriogenology ; 68(4): 654-62, 2007 Sep 01.
Article in English | MEDLINE | ID: mdl-17597198

ABSTRACT

The functional significance of male accessory sex glands (ASG) remains unclear. This study explored their importance in reproduction. In previous investigations, embryos sired by males with ASG either totally or partially removed had a shift in the cell cycle and delayed cleavage during preimplantation development, higher incidence of apoptosis, early oviductal-uterine transit, higher proportion of embryo degeneration, lower implantation rate, and ultimately reduced fertility and fecundity. Some pups were born alive; but would they be normal? We hypothesized that the first generation offspring (F1) could also bear undesirable traits. To test our hypothesis, we raised and studied these F1 pups from birth to 8 weeks. We monitored physical growth and assessed behaviour such as nest patch odor preference, acoustic startle response (ASR) and exploratory activity. We detected deviations from the norm in physical growth, a premature cessation of nest patch odor preferences, accelerated acoustic startle habituation and more frequent rearing when exposed to a novel environment. In terms of structure, we found one incidence of diphallus with duplicated urethra. We concluded that sperm lacking contact with ASG secretions gave rise to progeny with abnormal traits.


Subject(s)
Abnormalities, Multiple/etiology , Behavior, Animal/physiology , Genitalia, Male/physiology , Animals , Animals, Newborn , Birth Weight/physiology , Cricetinae , Embryonic Development/physiology , Female , Genitalia, Male/surgery , Male , Mesocricetus , Nesting Behavior/physiology , Odorants , Pregnancy , Random Allocation , Reflex, Startle
6.
Lupus ; 15(5): 276-81, 2006.
Article in English | MEDLINE | ID: mdl-16761501

ABSTRACT

The objective of this study was to compare the limit of agreement of creatinine clearance (CrCl) estimated by different equations with the CrCl measured by 24-hour urine collection in Hong Kong Chinese patients with systemic lupus erythematosus (SLE). Forty-three SLE patients with mild to moderate renal impairment (serum creatinine concentration >80 micromol/L to <300 micromol/L for females; and >106 micromol/L to <300 micromol/L for males) and not requiring renal replacement therapy were assessed. The estimated clearances were calculated by the Cockcroft-Gault (CG) equation, the Modification of Diet in Renal Disease (MDRD) study equation and the abbreviated MDRD (aMDRD) study equation. The estimated clearances were compared against the measured CrCl by 24-hour urine collection for their limit of agreement. Forty-three patients with mean (+/-SD) age of 41.6 (+/-8.4) years were assessed. As compared to the measured CrCl in patients with SLE, the clearances by CG equation, MDRD and aMDRD equations predicted a mean difference of -0.8% (95% confidence interval, -43.9-42.3%); -8.6% (95% CI, -24.3-7.2%) and -4.7% (95% CI, -21.4-12%), respectively. There is a tendency for the MDRD and aMDRD study equations to underestimate CrCl. The MDRD and aMDRD study equations have better predictive value than the CG equation.


Subject(s)
Glomerular Filtration Rate , Kidney Diseases/physiopathology , Kidney/physiology , Lupus Erythematosus, Systemic/physiopathology , Adult , Body Height , Body Surface Area , Body Weight , Case-Control Studies , Chromium Radioisotopes/pharmacokinetics , Creatinine/pharmacokinetics , Creatinine/urine , Female , Humans , Kidney Diseases/diagnosis , Kidney Diseases/urine , Male , Middle Aged , Predictive Value of Tests , Radiopharmaceuticals/pharmacokinetics , Reference Standards
7.
Cancer Gene Ther ; 13(6): 619-27, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16456550

ABSTRACT

Developing continuous systemic delivery of endostatin has been a goal of many laboratories. We have employed a method of gene therapy utilizing different viral constructs. Here, we report that a new serotype of adeno-associated viruses, which incorporates canine endostatin, provides dose-dependent transgene expression in the circulation after intramuscular injection in mice. Elevated levels of endostatin remained stable in the circulation for at least 4 months. In vitro assays determined that the protein expressed was biologically active. Antitumor activities of the above construct demonstrated a U-shape curve, where the maximum activity was observed within a certain critical concentration range. These data suggest that an optimum dose range may be required to achieve therapeutic efficacy in large animal models.


Subject(s)
Antineoplastic Agents/therapeutic use , Dependovirus/genetics , Endostatins/therapeutic use , Genetic Therapy/methods , Neoplasms/drug therapy , Amino Acid Sequence , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/therapeutic use , Animals , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/administration & dosage , Cell Line, Tumor , Cell Proliferation/drug effects , Dogs , Dose-Response Relationship, Drug , Endostatins/administration & dosage , Endostatins/genetics , Genetic Vectors , Humans , Injections, Intramuscular , Male , Mice , Mice, SCID , Molecular Sequence Data , Pancreatic Neoplasms/drug therapy , Sequence Alignment
8.
Bone Marrow Transplant ; 36(6): 491-7, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16044139

ABSTRACT

In an effort to improve the outcome of poor-risk lymphoma patients, we evaluated a novel regimen of tandem high-dose chemotherapy (THDC) with autologous stem cell transplantation. A total of 41 patients (median age 40 years, range 15-68 years) with poor-risk non-Hodgkin's lymphoma and Hodgkin's disease were enrolled. THDC consisted of melphalan (180 mg/m2) and escalating dose mitoxantrone (30-50 mg/m2) (MMt) for the first conditioning regimen, and thiotepa (500 mg/m2), carboplatin (800 mg/m2), and escalating dose etoposide phosphate (400-850 mg/m2), (ETCb) as the second regimen. In all, 31 patients (76%) completed both transplants, with a median time between transplants of 55 days (range 26-120). The maximum tolerated dose was determined as 40 mg/m2 for mitoxantrone and 550 mg/m2 for etoposide phosphate. The overall toxic death rate was 12%. Following high-dose chemotherapy, 10 of 24 evaluable patients (42%) were in CR. The two-year overall survival and event-free survival is 67% (95% CI, 52-81%) and 45%, (95% CI, 29-61%) for the 41 patients enrolled; and 69% (95% CI, 525-586%) and 48% (95% CI, 30-67%) for the 31 patients completing both transplants. This THDC regimen is feasible but with notable toxicity in heavily pretreated patients; its role in the current treatment of high-risk lymphoma remains to be determined.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Hematopoietic Stem Cell Transplantation/methods , Lymphoma/therapy , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/toxicity , Female , Hematopoietic Stem Cell Transplantation/mortality , Humans , Lymphoma/complications , Lymphoma/mortality , Male , Maximum Tolerated Dose , Melphalan/administration & dosage , Middle Aged , Mitoxantrone/administration & dosage , Pilot Projects , Risk , Survival Analysis , Transplantation Conditioning/methods , Transplantation, Autologous
9.
Stroke ; 33(3): 728-34, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11872896

ABSTRACT

BACKGROUND AND PURPOSE: Stroke patients may have an increased risk of fractures because of weak bones or an increased risk of falling. Our goal was to estimate the frequency of fracture after stroke and to identify those at greatest risk. METHODS: This study incorporated 2 complementary strategies: a prospective, single-center, cohort study and an analysis of Scottish routine hospital discharge data. RESULTS: Eighty-eight fractures (30% hip) occurred in 2696 hospital-referred stroke patients. The proportions sustaining any fracture or hip fracture within 2 years were 4% and 1.1%, respectively, 1.4 (95% CI, 0.92 to 2.07) times the rate of hip fracture in the general population (ie, observed number divided by expected number or standardized morbidity ratio). Female sex, older age, low abbreviated mental test score, and prestroke dependence were associated with an increased hip fracture rate. Routine data identified 129 935 acute stroke patients admitted to Scottish hospitals. During 363 447 patient-years, 4528 patients had hip fractures, 2.0% had fractures by 1 year, and 10.6% had fractures by 10 years. This is 1.7 times the rate of hip fracture in the general population and 2.3 times that in patients with myocardial infarction. Older patients predictably had the highest rate of poststroke hip fractures but a lower standardized morbidity ratio than younger patients. CONCLUSIONS: Fractures after stroke are probably frequent and serious enough to justify the development of preventive strategies, but the modest event rate would mean that randomized, controlled trials to test these strategies specifically in stroke patients would need to enroll thousands of patients.


Subject(s)
Fractures, Bone/classification , Fractures, Bone/epidemiology , Stroke/epidemiology , Age Factors , Aged , Aged, 80 and over , Cohort Studies , Comorbidity , Disease-Free Survival , Female , Follow-Up Studies , Fractures, Bone/diagnosis , Hip Fractures/classification , Hip Fractures/diagnosis , Hip Fractures/epidemiology , Humans , Incidence , Male , Morbidity , Prognosis , Prospective Studies , Scotland/epidemiology , Sex Factors
10.
Jpn J Cancer Res ; 92(8): 869-73, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11509119

ABSTRACT

We used our palindromic polymerase chain reaction (PCR)-driven cDNA differential display technique to identify and isolate a gene, designated periostin, from cancer tissues and found it to be overexpressed in several human tumors. We attempted to determine the influence of periostin expression on clinical outcome in patients with non-small cell lung cancer (NSCLC) by reverse transcriptase (RT)-PCR analysis. Periostin gene was highly expressed at the tumor periphery of lung cancer tissue but not within the tumor by in situ RNA hybridization, suggesting that expression of periostin may be involved in the process of tumor invasion. Periostin transcripts were detected in 50 (49.0%) of the tumor samples, although some paired normal lung samples showed weak expression. There was no relationship between periostin gene expression and gender, N- or T-status. The NSCLC patients with periostin expression had significantly poorer survival than the patients without periostin expression (P = 0.0338).


Subject(s)
Adenocarcinoma/diagnosis , Biomarkers, Tumor/genetics , Carcinoma, Non-Small-Cell Lung/diagnosis , Cell Adhesion Molecules/genetics , Lung Neoplasms/diagnosis , Adenocarcinoma/metabolism , Adenocarcinoma/mortality , Adult , Aged , Aged, 80 and over , Animals , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/mortality , DNA Primers/chemistry , Female , Humans , Immunoenzyme Techniques , In Situ Hybridization , Japan/epidemiology , Lung Neoplasms/metabolism , Lung Neoplasms/mortality , Lymphatic Metastasis/genetics , Male , Middle Aged , Prognosis , RNA, Messenger/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Survival Rate
11.
J Clin Oncol ; 19(10): 2739-45, 2001 May 15.
Article in English | MEDLINE | ID: mdl-11352967

ABSTRACT

PURPOSE: Most breast cancer survivors experience hot flashes; many use complementary or alternative remedies for these symptoms. We undertook a randomized clinical trial of black cohosh, a widely used herbal remedy for menopausal symptoms, among breast cancer patients. PATIENTS AND METHODS: Patients diagnosed with breast cancer who had completed their primary treatment were randomly assigned to black cohosh or placebo, stratified on tamoxifen use. At enrollment, patients completed a questionnaire about demographic factors and menopausal symptoms. Before starting to take the pills and at 30 and 60 days, they completed a 4-day hot flash diary. At the final visit, they completed another menopausal symptom questionnaire. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were measured in a subset of patients at the first and final visits. RESULTS: Of 85 patients (59 on tamoxifen, 26 not on tamoxifen) enrolled in the study, 42 were assigned to treatment and 43 were assigned to placebo; 69 completed all three hot flash diaries. Both treatment and placebo groups reported declines in number and intensity of hot flashes; the differences between the groups were not statistically significant. Both groups also reported improvements in menopausal symptoms that were, for the most part, not significantly different. Changes in blood levels of FSH and LH also did not differ in the two groups. CONCLUSION: Black cohosh was not significantly more efficacious than placebo against most menopausal symptoms, including number and intensity of hot flashes. Our study illustrates the feasibility and value of standard clinical trial methodology in assessing the efficacy and safety of herbal agents.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Hot Flashes/drug therapy , Plant Extracts/therapeutic use , Tamoxifen/therapeutic use , Antineoplastic Agents, Hormonal/adverse effects , Breast Neoplasms/radiotherapy , Combined Modality Therapy , Double-Blind Method , Female , Follicle Stimulating Hormone/blood , Humans , Luteinizing Hormone/blood , Middle Aged , Tamoxifen/adverse effects
12.
J Cell Biol ; 152(6): 1233-46, 2001 Mar 19.
Article in English | MEDLINE | ID: mdl-11257123

ABSTRACT

Collagen XVIII (c18) is a triple helical endothelial/epithelial basement membrane protein whose noncollagenous (NC)1 region trimerizes a COOH-terminal endostatin (ES) domain conserved in vertebrates, Caenorhabditis elegans and Drosophila. Here, the c18 NC1 domain functioned as a motility-inducing factor regulating the extracellular matrix (ECM)-dependent morphogenesis of endothelial and other cell types. This motogenic activity required ES domain oligomerization, was dependent on rac, cdc42, and mitogen-activated protein kinase, and exhibited functional distinction from the archetypal motogenic scatter factors hepatocyte growth factor and macrophage stimulatory protein. The motility-inducing and mitogen-activated protein kinase-stimulating activities of c18 NC1 were blocked by its physiologic cleavage product ES monomer, consistent with a proteolysis-dependent negative feedback mechanism. These data indicate that the collagen XVIII NC1 region encodes a motogen strictly requiring ES domain oligomerization and suggest a previously unsuspected mechanism for ECM regulation of motility and morphogenesis.


Subject(s)
Bacterial Proteins , Cell Movement/physiology , Collagen/metabolism , Endothelium, Vascular/cytology , Extracellular Matrix/physiology , Peptide Fragments/metabolism , Protein Structure, Tertiary , Angiogenesis Inhibitors/genetics , Angiogenesis Inhibitors/metabolism , Animals , Bacterial Toxins/pharmacology , Blotting, Western , Cell Movement/drug effects , Cells, Cultured , Collagen/chemistry , Collagen/genetics , Collagen Type XVIII , Cytotoxins/pharmacology , Dimerization , Endostatins , Endothelium, Vascular/drug effects , Endothelium, Vascular/growth & development , Humans , Mice , Mitogen-Activated Protein Kinases/metabolism , Morphogenesis , Peptide Fragments/chemistry , Peptide Fragments/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , cdc42 GTP-Binding Protein/genetics , cdc42 GTP-Binding Protein/metabolism , rac GTP-Binding Proteins/genetics , rac GTP-Binding Proteins/metabolism , rho GTP-Binding Proteins/metabolism
13.
J Natl Cancer Inst ; 93(5): 382-7, 2001 Mar 07.
Article in English | MEDLINE | ID: mdl-11238700

ABSTRACT

BACKGROUND: Angiogenesis is essential for tumor growth and progression. Therefore, inhibition of angiogenesis is being studied as a new anticancer therapy. Because cytotoxic chemotherapy is more effective on rapidly growing tumors than on slowly growing tumors, it has been assumed that antiangiogenic therapy will also be effective only on rapidly growing, highly vascularized tumors. We compared the effects of two angiogenesis inhibitors, TNP-470 and angiostatin, on slowly growing, poorly vascularized and rapidly growing, highly vascularized human tumors in mice. METHODS: Slowly growing (RT-4) and rapidly growing (MGH-U1) human bladder carcinoma cell lines were grown in severe combined immunodeficiency mice. Established tumors were treated with one of the two angiogenesis inhibitors. Tumor volumes, vascularity, and proliferation indices were determined. The in vitro effects of TNP-470 and of angiostatin on the proliferation of RT-4 and MGH-U1 cells were also investigated. All statistical tests were two-sided. RESULTS: RT-4 and MGH-U1 tumor growth was statistically significantly inhibited by both angiogenesis inhibitors (P<.001). Both inhibitors decreased the blood vessel density in both tumor types but did not alter the in vivo proliferation indices of the tumors. TNP-470, but not angiostatin, marginally decreased the in vitro proliferation of MGH-U1 cells. CONCLUSION: Slowly growing, poorly vascularized tumors in animal models respond as well as rapidly growing, highly vascularized tumors to therapy with the angiogenesis inhibitors TNP-470 and angiostatin.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Antineoplastic Agents/pharmacology , Neovascularization, Pathologic/drug therapy , Peptide Fragments/pharmacology , Plasminogen/pharmacology , Sesquiterpenes/pharmacology , Urinary Bladder Neoplasms/blood supply , Urinary Bladder Neoplasms/drug therapy , Angiostatins , Animals , Carcinoma/blood supply , Carcinoma/drug therapy , Cyclohexanes , Humans , Immunohistochemistry , Mice , Mice, SCID , O-(Chloroacetylcarbamoyl)fumagillol
14.
Met Based Drugs ; 8(2): 107-11, 2001.
Article in English | MEDLINE | ID: mdl-18475983

ABSTRACT

Bacterial screening employing the agar diffusion test on triphenyltin carboxylates containing various functional residues in the ester moiety revealed appreciable differences in their activities relative to triphenyltin acetate. Among these, [3-(Diethylphosphono)propionato] triphenyltin (1) and [N-cyclohexylcarbamoyl) glycinato] triphenyltin displayed activities comparable to tri-n-butyltin cinnamate (2) towards both Gram-positive and Gram-negative bacteria; the latter compound was the most active among the eleven triorganotin compounds tested, which included cyclopentyldiphenyltin hydroxide (3) and its methacrylate derivative. Applying the more quantitative plate count and optical density tests on compounds 1-3, it was shown that their inhibitory activity ranked in the order 2 > 3 >1. Significantly, 3 caused around 90% inhibition of both Eschechia coli (-) and Pseudomonas aeruginosa (-) when incubated for 24 h at 37+/-1 at the 10.0 mug/ mL concentration level. Compound 2 was less effective against P.aeruginosa than against E.coli. While the Gram-positive bacteria were all readily inhibited, Bacillus subtilis (+) appeared to the most susceptible among them towards the test compounds.

15.
Conn Med ; 63(10): 583-4, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10578547

ABSTRACT

BACKGROUND: Vincristine-associated peripheral neuropathy is a well-described entity. We describe a case of vincristine-induced vocal cord paralysis, which is a rare complication of this drug. We report herein the second case of bilateral vocal cord paralysis in a patient receiving conventional doses of vincristine. OBJECTIVE: To present a case report of vincristine-associated vocal cord paralysis and to review the relevant English language literature on this subject. DESIGN: Report and review of the literature. SETTING: Outpatient community cancer center. PATIENT: A 58-year-old female with a diffuse large cell lymphoma stage IV receiving cyclophosphamide, doxorubicin, vincristine, and prednisone. RESULTS: Bilateral vocal cord paralysis occurred in this patient receiving vincristine as part of her chemotherapy regimen. In addition to this case there have been a total of 25 prior reports, which are reviewed in the text. CONCLUSION: The incidence of bilateral vocal cord paralysis in patients receiving vincristine on the usual low-dose schedule is low. Prompt withdrawal of the offending agent results in prompt recovery without untoward long-lasting sequela.


Subject(s)
Antineoplastic Agents, Phytogenic/adverse effects , Vincristine/adverse effects , Vocal Cord Paralysis/chemically induced , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Female , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Middle Aged
16.
Cancer Res ; 59(9): 2023-8, 1999 May 01.
Article in English | MEDLINE | ID: mdl-10232579

ABSTRACT

Using the palindromic PCR-cDNA display method, we have cloned a novel gene overexpressed by human colon carcinoma relative to normal colon. Among normal tissues examined, only testis expresses it at a high level. Sequence analysis revealed its extensive homology with checkpoint genes rad17 of Schizosaccharomyces pombe and RAD24 of Saccharomyces cerevisiae. This novel gene designated as hRad17 is localized to chromosome 5q12,13.1, a region known to be deleted in a variety of human cancers. Promoter region and one pseudogene of hRad17 have been identified. Whereas the increased expression of hRad17 by human colon carcinomas may be related to the known resistance of these cells to DNA-damaging agents during therapy, the deletion of hRad17 in a variety of cancers may predispose them to increased rate of mutation and heightened sensitivity to DNA-damaging agents, including radiation and anticancer drugs.


Subject(s)
Carcinoma/metabolism , Cell Cycle Proteins/biosynthesis , Cell Cycle Proteins/genetics , Cell Cycle/genetics , Chromosomes, Human, Pair 5/genetics , Colorectal Neoplasms/metabolism , Fungal Proteins/genetics , Gene Expression Regulation, Neoplastic , Genes , Neoplasm Proteins/biosynthesis , Saccharomyces cerevisiae/genetics , Schizosaccharomyces/genetics , Animals , Base Sequence , Carcinoma/genetics , Chlorocebus aethiops/genetics , Cloning, Molecular , Colorectal Neoplasms/genetics , DNA Damage , DNA, Complementary/genetics , DNA-Binding Proteins , Gene Deletion , Genes, Fungal , Humans , Intracellular Signaling Peptides and Proteins , Male , Mice , Molecular Sequence Data , Neoplasm Proteins/genetics , Nuclear Proteins , Polymerase Chain Reaction , Promoter Regions, Genetic , Pseudogenes/genetics , Saccharomyces cerevisiae Proteins , Schizosaccharomyces pombe Proteins , Testis/metabolism
17.
Cancer Res ; 59(9): 2159-66, 1999 May 01.
Article in English | MEDLINE | ID: mdl-10232603

ABSTRACT

Fusion proteins between whole antibodies (Abs) and cytokines (immunocytokines) such as interleukin 2 have shown efficacy in several mouse tumor models despite a circulating half-life that is significantly shorter than that of the original Ab. We have examined the potential mechanisms responsible for clearance and shown that an important factor is enhanced binding to Fc receptor (FcR). Improvements in the half-lives of two different immunocytokines were made by changing the isotype of the human heavy chain C region from IgG1 or IgG3 to those with reduced binding to FcR, e.g., IgG4. The same effect could also be achieved through site-directed mutagenesis of the FcR binding site in the IgG1 H chain. In vitro studies using mouse J774 FcR-expressing cells showed increased binding of interleukin 2-based immunocytokines, relative to their corresponding Abs, and that this was reversed in those fusion proteins made with IgG4 or mutated IgG1 H chains. All of the fusion proteins showing reduced FcR binding also had reduced Ab-dependent cellular cytotoxicity activity, as measured in 4-h chromium release assays. A complete loss of complement-dependent cytotoxicity activity was seen with an IgG4-based immunocytokine derived from an IgG1 Ab with potent activity. Despite these reduced effector functions, the IgG4-based immunocytokines with extended circulating half-lives showed equivalent (in the case of severe combined immunodeficiency mouse xenograft models) or better (in the case of syngeneic models) efficacy in mouse tumor models than the original IgG1-based molecules. These novel immunocytokines may show improved efficacy in therapeutic situations where T cell- rather than natural killer- or complement-mediated antitumor mechanisms are involved.


Subject(s)
Genes, Immunoglobulin , Immunoconjugates/metabolism , Immunoglobulin G/metabolism , Immunoglobulin Heavy Chains/metabolism , Interleukin-2/metabolism , Receptors, Fc/metabolism , Recombinant Fusion Proteins/metabolism , Animals , Antibody-Dependent Cell Cytotoxicity , Binding Sites , Carcinoma/pathology , Carcinoma/therapy , Complement System Proteins/immunology , Cytotoxicity, Immunologic , Humans , Immunoconjugates/pharmacokinetics , Immunoconjugates/therapeutic use , Immunoglobulin G/genetics , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Isotypes/metabolism , Interleukin-2/genetics , Kidney Neoplasms/pathology , Male , Melanoma, Experimental/pathology , Melanoma, Experimental/therapy , Metabolic Clearance Rate , Mice , Mice, Inbred BALB C , Mice, SCID , Mutagenesis, Site-Directed , Prostatic Neoplasms/pathology , Recombinant Fusion Proteins/pharmacokinetics , Recombinant Fusion Proteins/therapeutic use , Tissue Distribution , Transfection , Transplantation, Heterologous , Tumor Cells, Cultured
18.
Science ; 284(5415): 808-12, 1999 Apr 30.
Article in English | MEDLINE | ID: mdl-10221914

ABSTRACT

Solid tumors depend on angiogenesis for their growth. In a transgenic mouse model of pancreatic islet cell carcinogenesis (RIP1-Tag2), an angiogenic switch occurs in premalignant lesions, and angiogenesis persists during progression to expansive solid tumors and invasive carcinomas. RIP1-Tag2 mice were treated so as to compare the effects of four angiogenesis inhibitors at three distinct stages of disease progression. AGM-1470, angiostatin, BB-94, and endostatin each produced distinct efficacy profiles in trials aimed at preventing the angiogenic switch in premalignant lesions, intervening in the rapid expansion of small tumors, or inducing the regression of large end-stage cancers. Thus, anti-angiogenic drugs may prove most efficacious when they are targeted to specific stages of cancer.


Subject(s)
Antineoplastic Agents/pharmacology , Carcinoma, Islet Cell/drug therapy , Neovascularization, Pathologic/prevention & control , Pancreatic Neoplasms/drug therapy , Angiostatins , Animals , Anticarcinogenic Agents/pharmacology , Apoptosis , Carcinoma, Islet Cell/blood supply , Carcinoma, Islet Cell/pathology , Carcinoma, Islet Cell/prevention & control , Collagen/pharmacology , Cyclohexanes , Disease Progression , Drug Evaluation, Preclinical , Endostatins , Female , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neoplasm Staging , O-(Chloroacetylcarbamoyl)fumagillol , Pancreatic Neoplasms/blood supply , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/prevention & control , Peptide Fragments/pharmacology , Phenylalanine/analogs & derivatives , Phenylalanine/pharmacology , Plasminogen/pharmacology , Sesquiterpenes/pharmacology , Thiophenes/pharmacology
19.
Protein Eng ; 11(6): 495-500, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9725629

ABSTRACT

We have developed a general expression system that enhances the production and secretion of proteins in mammalian cells. The protein of interest is expressed as a fusion to a signal peptide and the Fc fragment of immunoglobulin as the N-terminal fusion partner, which can direct the cellular processes into expressing and secreting high levels of many different types of proteins. These include secretory proteins, enzymes and soluble domains of membrane proteins, as well as nuclear and regulatory proteins. Typical expression levels of these proteins from stable cell lines ranged from several to 100 microg/ml in conditioned media. The Fc domain helps to solubilize hydrophobic proteins and provides a handle for easy detection and purification of the fusion proteins; and it can be cleaved off by treatment with protease if desired.


Subject(s)
Antigens, Surface , Gene Expression , Immunoglobulin Fc Fragments/genetics , Protein Sorting Signals/genetics , Recombinant Fusion Proteins , Animals , Antibodies, Monoclonal/biosynthesis , Carboxypeptidases/immunology , Culture Media, Conditioned , Dimerization , Dipeptidyl Peptidase 4/metabolism , Disulfides/metabolism , Genetic Vectors , Glutamate Carboxypeptidase II , Glycosylation , Humans , Immunoglobulin Fc Fragments/immunology , Immunoglobulin gamma-Chains/genetics , Immunoglobulin kappa-Chains/genetics , Mice , Mutagenesis , Restriction Mapping , Transfection , Tumor Cells, Cultured
20.
Proc Natl Acad Sci U S A ; 95(18): 10443-8, 1998 Sep 01.
Article in English | MEDLINE | ID: mdl-9724722

ABSTRACT

The crystal structure of human endostatin reveals a zinc-binding site. Atomic absorption spectroscopy indicates that zinc is a constituent of both human and murine endostatin in solution. The human endostatin zinc site is formed by three histidines at the N terminus, residues 1, 3, and, 11, and an aspartic acid at residue 76. The N-terminal loop ordered around the zinc makes a dimeric contact in human endostatin crystals. The location of the zinc site at the amino terminus, immediately adjacent to the precursor cleavage site, suggests the possibility that the zinc may be involved in activation of the antiangiogenic activity following cleavage from the inactive collagen XVIII precursor or in the cleavage process itself.


Subject(s)
Collagen/chemistry , Peptide Fragments/chemistry , Zinc/chemistry , Base Sequence , Binding Sites , Collagen/metabolism , Collagen Type XVIII , Crystallography, X-Ray , DNA Primers , Dimerization , Endostatins , Heparin/metabolism , Humans , Peptide Fragments/metabolism , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...